Bioaffinity Technologies Inc.
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 17 institutions reported holding Bioaffinity Technologies Inc. in their 13F filings, up 3 from Q1 2024. 5 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($372K), Geode Capital Management, LLC ($150K) and Captrust Financial Advisors ($60K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Bioaffinity Technologies Inc.
- CUSIP
- 09076W109
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $73K |
| Exits | 2 | $293 |
All 13F filers, Q1 2024 → Q2 2024: 174,683 shares bought and 14,678 shares sold, net +160,005 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Vanguard Group Inc. | 0.00% | Add +144.6% | 171,994 | $372K |
| Geode Capital Management, LLC | 0.00% | Add +65.4% | 69,600 | $150K |
| Captrust Financial Advisors | 0.00% | No change | 27,885 | $60K |
| Renaissance Technologies | 0.00% | Reduce -38.8% | 22,967 | $50K |
| Ground Swell Capital, LLC | 0.05% | New | 22,864 | $49K |
| State Street Corp. | 0.00% | No change | 17,600 | $38K |
| Sheaff Brock Investment Advisors, LLC | 0.00% | Add +50.0% | 15,000 | $32K |
| Northern Trust Corp. | 0.00% | No change | 13,662 | $30K |
| Creative Planning | 0.00% | Add +4.1% | 12,595 | $27K |
| IFP Advisors, Inc | 0.00% | Add +100.0% | 10,000 | $22K |
| UBS Group AG | 0.00% | New | 9,591 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +37.9% | 4,615 | $10K |
| Morgan Stanley | 0.00% | New | 1,000 | $2K |
| Cypress Capital, LLC | 0.00% | New | 200 | $432 |
| Bank of America Corp. | 0.00% | New | 65 | $140 |
| Qube Research & Technologies Ltd | 0.00% | No change | 38 | $82 |
| JPMorgan Chase & Co. | 0.00% | Add +38.5% | 18 | $39 |
"% of holder's portfolio" is BIOAFFINITY TECHNOLOGIES INC's weight in each manager's 13F, not the share of Bioaffinity Technologies Inc. the manager owns.